A controlled clinical trial of chlormezanone, orphenadrine, orphenadrine/paracetamol and placebo in the treatment of painful skeletal muscle spasms.
Four hundred patients with painful muscle spasm caused by five common musculoskeletal diseases were included in a double-blind controlled trial of chlormezanone, orphenadrine, orphenadrine/paracetomol and placebo. Patients were treated for one week and then asked for their subjective assessment of the treatment. Fifty-three per cent improved on placebo, 57 percent on chlormezanone, 66 percent on orphenadrine and 71 percent on orphenadrine/paracetamol. There was no significant difference between chlormezanone and placebo, but orphenadrine appeared to have a beneficial effect, presumably because of its muscle relaxant activity.
D000082:Acetaminophen / Q000627:therapeutic use*; D002720:Chlormezanone / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D009120:Muscle Cramp / Q000188:drug therapy*; D009966:Orphenadrine / Q000627:therapeutic use*; D010919:Placebos
D010919:Placebos; D000082:Acetaminophen; D009966:Orphenadrine; D002720:Chlormezanone